Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists

Journal of Medicinal Chemistry

Volumn 49, Issue 10, 2006, Pages 2851-2857

  Palani, Anandan ^a   Tagat, Jayaram R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; APLAVIROC; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NICOTINAMIDE; PIPERIDINE DERIVATIVE; TAK 652; UNCLASSIFIED DRUG; VICRIVIROC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; HEART DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; NONHUMAN; QT PROLONGATION; SHORT SURVEY; SYSTEMATIC REVIEW;

ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; HIV ENVELOPE PROTEIN GP120; HUMANS; RECEPTORS, CCR5;

EID: 33646755473     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060009x     Document Type: Short Survey

References (61)

1. UNAIDS. Report on the Global HIV/AIDS Epidemic 2000. Presented at the 13th International AIDS Conference, Durban, South Africa, 2000.
2. AIDS Epidemic Update, December 2005; UNAIDS/03.39E; World Health Organization, 2005 (www.who.int/hiv/epi-update 2005_en.pdf).
3. (a) Richman, D. D. HIV chemotherapy. Nature 2001, 410, 995-1001.
4. (b) Fauci, A. S. HIV and AIDS: 20 years of science. Nat. Med. 2003, 9, 839-843.
5. (a) Carr, A. Toxicity of antiretroviral therapy and implications for drug development. Nat. Rev. Drug Discovery 2003, 2, 624-634.
6. (b) Duran, S.; Saves, M.; Spire, B.; Cailleton, V.; Sobel, A.; Carrieri, P.; Salmon, D.; Moatti, J.-P.; Leport, C. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001, 15, 2441-2444.
7. Fumero, E.; Podzamczer, D.; New patterns of HIV-1 resistance during HAART. Clin. Microbiol. Infect. 2003, 9, 1077.
8. Ickovics, J. R.; Meade, C. S. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Care 2002, 14, 309-318.
9. Lin, P. F.; Blair, W.; Wang, T.; Spicer, T.; Guo, Q.; Zhou, N.; Gong, Y.-F.; Wang, H.-G. H.; Rose, R.; Yamanaka, G.; Robonson, B.; Li, C.-B.; Fridell, R.; Deminie, C.; Demers, G.; Yang, Z.; Zadjura, L.; Meanwell, N.; Colonno, R. From the cover: A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 11013-11018.
10. De Clerq, E. Timeline: The bicyclam AMD3100 story. Nat. Rev. Drug Discovery 2003, 2, 581-587.
11. Dando, T. M.; Perry, C. M. Enfuvirtide. Drugs 2003, 63, 2755-2766.
12. (a) Kirkpatrick, P.; Labonte, J.; Lebbos, J. HIV: No entry. Nat. Rev. Drug Discovery 2003, 2, 345-346.
13. (b) Este, J. A. Virus entry as a target for anti-HIV intervention. Curr. Med. Chem. 2003, 10, 1617-1632.
14. Maddon, P. J.; Dalgleish, A. G.; McDougal, J. S.; Clapham, P. R.; Weiss, R. A.; Axel, R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986, 47 (3), 33-48.
15. Berger, E. A.; Murphy, P. M.; Farber, J. M. Chemokine receptors as HIV-1 co-receptors. Roles in viral entry, tropism and disease. Annu. Rev. Immunol. 1999, 17, 657-700.
16. Mathews, T.; Salgo, M.; Greenberg, M.; Chung, J.; DeMasi, R.; Bolognesi, D. Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. 2004, 3, 215-225.
17. Recent Reviews: (a) Kazmierski, W.; Bifulco, N.; Yang, H.; Boone, L.; DeAnda, F.; Watson, C.; Kenakin, T. Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg. Med. Chem. 2003. 11, 2663-2676.
18. (b) Maeda, K.; Nakata, H.; Ogata, H.; Koh, Y.; Miyakawa, T.; Mitsuya, H. The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection. Curr. Opin. Pharmacol. 2004, 4, 447-452.
19. (c) Barber, C. G. CCR5 antagonists for the treatment of HIV. Curr. Opin. Invest. Drugs 2004, 5, 851-861.
20. (d) Rusconi, S.; Scozzafava, A.; Mastrolorenzo, Supuran, C. T. New advances in HIV entry inhibitors development. Curr. Drug Targets: Infect. Disord. 2004, 4, 339-355.
21. (e) Barbaro, G.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Highly active antiretriviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr. Pharm. Des. 2005, 11, 1805-1843.
22. (f) Kazmierski, W.; Jennifer, P.; Maosheng. D.; Terry, K.; Stephen, J.; Kristjan, G. S.; Stephen, P. C.; Paul, F. L. Recent progress in the discovery of new CCR5 and CXCR4 chemokine receptor antagonists as inhibitors of HIV-1 entry. Part 2. Curr. Med. Chem.: Anti-Infect. Agents 2005, 4, 133-152.
23. (g) Westby, M.; van der Ryst, E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antiviral Chem. Chemother. 2005, 16, 339-354.
24. (h) Lylea, T. A.; Millerb, M. D. New developments in HIV therapeutics. Annu. Rep. Med. Chem. 2005, 40, 290-300.
25. + T cells. Science 1995, 270, 1811.
26. (b) Simmons, G.; Clapham, P. R.; Picard, L.; Offord, R. E.; Rosenkilde, M. M.; Schwartz, T. W.; Buser, R.; Wells, T. N. C.; Proudfoot, A. E. I. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997, 276, 276.
27. (a) Huffnagle, G. B.; Mcneil, L. K.; McDonald, R. A.; Murphy, J. W.; Toews, G. B.; Maeda, N.; Kuziel, W. A. Role of c-c chemokine receptor 5 in organ specific and innate immunity to Cryptococcus neoformans. J. Immunol. 1999, 163, 4642-4646.
28. (b) Barr, E. L.; Ouburg, S.; Igietseme, J. U.; Morre, S. A.; Okwandu, E.; Eko, F. O.; Ifere, G.; Belay, T.; He, Q.; Lyn, D.; Nwankwo, G.; Lillard, J.; Black, C. M.; Ananaba, G. A. Host inflammatory response and development of complications of Chlamydia trachomatis genital infection in CCR5-deficient mice and subfertile women with the CCR5delta32 gene deletion. J. Microbiol. Immunol. Infect. 2005, 38 (4), 244-254.
29. (c) Ank, N.; Peterson, K.; Malmgaard, L.; Mogensen S. C.; Pauldan, S. R. Age dependent role for CCR5 in antiviral host defense against herpes simplex virus type 2. J. Virol. 2005, 79 (15), 9831-9841.
30. (d) Ajuebor, M.; Aspinall, A. I.; Zhou, F.; Le, T.; Yang, Y.; Urbanski, S.; Sidobre, S.; Kronenberg, M.; Hogaboam, C.; Swain, M. G. Lack of chemokine receptor CCR5 promotes murine fulminant liver failure by preventing the apoptosis of activated CD1d-restricted NKT cells. J. Immunol. 2005, 2, 8027-8037.
31. (e) Moreno, C.; Gustot, T.; Nicaise, C.; Quertinmont, E.; Nagy, N.; Parmentier, M.; Le Moine, O.; Deviere, J.; Louis, H. Hepatology 2005, 42, 854-862.
32. Liu, R.; Paxton, W. A.; Choe, S.; Ceradini, D.; Martin, S. R.; Horuk, R.; Macdonald, M. E.; Stuhlmann, H.; Koup, R. A.; Landau, N. R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiple-exposed individuals to HIV-1 infection. Cell 1996, 86, 367-377.
33. Michael, N. L.; Chang, G.; Louie, L. G.; Mascola, J. R.; Dondero, D.; Birx, D. L.; Sheppard, H. W. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat. Med. 1997, 3, 338-340.
34. Connor, R. I.; Sheridan, K. E.; Ceradini, D.; Choe, S.; Landau, N. R. Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J. Exp. Med. 1997, 185, 621-628.
35. de Roda Husman, A. M.; Schuitemaker, H. Chemokine receptors and the clinical course of HIV-1 infection. Trends Microbiol. 1998, 6, 244-249.
36. Trkola, A.; Kuhmann, S. E.; Strizki, J. M.; Maxwell, E.; Ketas, T.; Morgan, T. Pugach, P.; Xu, S.; Wojcki, L.; Tagat, J.; Palani, A.; Shapiro, S.; Clader, J. W.; McCombie, S.; Reyes, G. R.; Baroudy, B. M.; Moore, J. P. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Nat. Acad. Sci. U.S.A. 2002, 99, 395.
37. (a) NK1-3: Duffy, R. A. Expert Opin. Emerging Drugs. 2004, 9, 9.
38. (b) NPY: Stamford, A. W.; Hwa, J.; van Heek, M. Recent developments in NPY receptor modulators. Annu. Rep. Med. Chem. 2003, 38, 61-70.
39. (c) M1-M5: Clader, J. W.; Billard, W.; Binch, H., III; Chen, L.-Y.; Crosby, G., Jr.; Duffy, R. A.; Ford, J.; Kozlowski, J. A.; Lachowicz, J. E.; Li, S.; Liu, C.; McCombie, S.; Vice, S.; Zhou, G.; Greenlee, W. J. Muscarinic antagonists: Anthranilamide derivatives with exceptional selectivity and in vivo activity. Bioorg. Med. Chem. 2004, 12, 319-326.
40. Takeda: (a) Shiraishi, M.; Aramaki, Y.; Seto, M.; Imoto, H.; Nishikawa, Y.; Kanzaki, N.; Okamoto, M., Sawada, H.; Nishimura, O.; Baba, M.; Fujino, M. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J. Med Chem. 2000, 43 (10), 2049-2063.
41. (b) Seto, M.; Aramaki, Y.; Okawa, T.; Miyamoto, N.; Aikawa, K.; Kanzaki, N.; Niwa, S.; Iizawa, Y.; Baba, M.; Shiraishi, M. Orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activity of 1-benzothiepine 1,1-dioxide and 1-benzazepine derivatives containing a tertiary amine moiety. Chem. Pharm. Bull. (Tokyo) 2004, 52, 577-590.
42. (c) Nishikawa, M.; Takashima, K.; Nishi, T.; Furuta, R. A.; Kanzaki, N.; Yamamoto, Y.; Fujisawa, J.-I. Analysis of binding sites for the new small molecule CCR5 antagonist TAK-220 on human CCR5. Antimicrob. Agents Chemother. 2005, 49, 4708-4715.
43. (d) Lizawa, Y.; Kanazaki, N.; Takashima, K.; Miyake, H.; Tagawa, Y.; Sugihara, Y.; Baba, M.; Anti-HIV-1 activity of TAK-220, a small molecule CCR5 antagonist. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003.
44. (e) Baba, M.; Takashima, K.; Miyake, H.; Kanzaki, N.; Teshima, K.; Wang, X.; Shirashi, M.; Iizawa, Y. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type-1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob. Agents Chemother. 2005, 49, 4584-4591.
45. Sch-C: (a) Palani, A.; Shapiro, S.; Clader, J. W.; Greenlee, W. J.; Cox, K.; Strizki, J.; Endres, M.; Baroudy, B. M. Discovery of 4-[(Z)-(4-bromophenyl) (ethoxyimino)methyl]-1′-[(2,4-dimethyl-3-pyridinyl)-carbonyl] -4′-methyl-1,4′-bipiperidine N-oxide (1): An orally bioavailable human CCR5 antagonist for the treatment of HIV infection. J. Med. Chem. 2001, 44 (21), 3339-3342.
46. (b) Strizki, J. M.; Xu, S.; Wagner, N. E.; Wojcik, L.; Liu, J.; Hou, Y.; Endres, M.; Palani, A.; Shapiro, S.; Clader, J. W.; Greenlee, W. J.; Tagat, J. R.; McCombie, S.; Cox, K.; Fawzi, A. B.; Chou, C. C.; Pugliese-Sivo, C.; Davies, L.; Moreno, M. E.; Ho, D. D.; Trkola, A.; Stoddart, C. A.; Moore, J. P.; Reyes, G. R.; Baroudy, B. M. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (22), 12718-12723.
47. (c). Reynes, J.; Rouzier, R.; Kanouni, T.; Baillat, V.; Baroudy, B.; Keung, A.; Hogan, C.; Markowitz, M.; Laughlin, M. SCH-C: Safety and antiviral effects of a CCR5 receptor antagonist in HIV-1 infected subjects. Presented at the 9th Coference on Retroviruses and Opportunisic Infections, Seattle, WA. Feburary 24-28, 2002; Abstract 1, p 53.
48. Sch-D: (a) Tagat, J. R.; McCombie, S. W.; Steensma, R. W.; Lin, S.-I.; Nazareno, D. V.; Baroudy, B.; Vantuno, N.; Xu, S.; Liu, J. Piperazine-based CCR5 antagonists as HIV-1 inhibitors I: 2(S)-Methyl piperazine as a key pharmacophore element. Bioorg. Med. Chem. Lett. 2001, 11, 2143-2146.
49. (b) Tagat, J. R.; Steensma, R. W.; McCombie, S. W.; Nazareno, D. V.; Lin, S.; Neustadt, B. R.; Cox, K.; Xu, S.; Wojcik, L.; Murray, M. G.; Vantuno, N.; Baroudy, B. M.; Strizki, J. M. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II: The discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-trifluoromehtyl)phenyl]ethyl]-1-piperazinyl] piperidine N1-oxide (Sch 350634), an orally bioavailable, potent CCR5 antagonist. J. Med Chem. 2001, 44, 3343-3346.
50. (c) McCombie, S. W.; Tagat, J. R.; Vice, S.; Lin, S.-I.; Steensma, R.; Palani, A.; Neustadt, B.; Baroudy, B.; Strizki, J. M.; Endres, M.; Cox, K.; Dan, N.; Chou, C.-C. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: Synthesis, anti-viral and pharmacokinetic profiles of symmetrical, heteroaryl carboxamides. Bioorg. Med. Chem. Lett. 2003, 13, 567-571.
51. (d) Tagat, J. R.; McCombie, S. W.; Nazareno, D.; Labroli, M. A.; Xiao, Y.; Steensma, R. W.; Strizki, J. M.; Baroudy, B. M.; Cox, K.; Lachowicz, J.; Varty, G.; Watkins, R. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV: Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)- 4-(trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective and orally bioavailable CCR5 antagonist. J. Med. Chem. 2004, 47, 2405-2408.
52. (e) Strizki, J. M.; Tremblay, C.; Xu, S.; Wojcki, L.; Wagner, N.; Gonsiorek, W.; Hipkin, W.; Chou, C.-C.; Pugliesie-Sivo, C.; Xiao, Y.; Tagat, J. R.; Cox, K.; Priestley, T.; Sorota, S.; Huang, W.; Hirsch, M.; Reyes, G. R.; Baroudy, B. M. Discovery and characterization of Vicriviroc (Sch-417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type-1. Antimicrob. Agents Chemother. 2005, 49, 4911-4919.
53. (f) Schurmann, D.; Rouzier, R.; Nougarede, R.; Reynes, J.; Fatkenheuer, G.; Raffi, F.; Michelet, C.; Tarral, A.; Hoffman, C.; Kiunke, J. Sch-D (Sch-417690): Anti-viral activity of a CCR5 receptor antagonist. Presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Fransisco, CA, February 8-11, 2004; Abstract 140 LB.
54. Seibert, C.; Sakmar, T. Small-molecule antagonists of CCR5 and CXCR4: A promising new class of anti-HIV-1 drugs. Curr. Pharm. Des. 2004, 10, 2041-2062.
55. Pfizer: (a) Wood, A.; Armour, D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog. Med. Chem. 2005, 43, 239-271.
56. (b) Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C.; Webster, R.; Armour, D.; Price, D.; Stammen, B.; Wood, A.; Perros, M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type-I activity. Antimicrob. Agents Chemother. 2005, 49, 4721-4732.
57. (c) Pozniak, A. L.; Fatkenheuer, G.; Johnson, M.; Hoepelman, I. M.; Rockstroh, J. K.; Goebel, F.; Abel, S.; James, I.; Rosario, M.; Medhurst, C.; Sullivan, J.; et al. Effect of short-term monotherapy with UK-427,-857 on viral load in HIV-infected patients. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, September 14-17, 2003; Abstract H-443.
58. Glaxo: (a) Takaoka, Y.; Okamoto, M.; Genba, Y.; Ohie, K. Novel crystals of triazaspiro[5.5]undecane derivative. WO-2004026874, 2004.
59. (b) Maeda, K.; Yoshimura, K.; Shibayama, S.; Habashita, H.; Tada, H.; Sagwa, K.; Miyakawa, T.; Aoki, M.; Fukushima, D.; Mitsuya, H. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J. Biol. Chem. 2001, 276, 35194-35200.
60. (c) Lalezari, J.; Thompson, M.; Kumar, P.; Piliero, P.; Davey, R.; Murtaugh, T.; Patterson, K.; Shachoy-Clark, A.; Adkison, K.; Demarest, J.; Sparks, S.; Fang, L.; Lou, Y.; Berrey, M.; Piscitelli, S. 873140, a novel CCR5 antagonist: antiviral activity and safety during short-term monotherapy in HIV-infected adults. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, D.C., October 30 through November 2, 2004; Abstract H-1137b.
61. Merck: Mills, S. G.; DeMartino, J. A. Chemokine receptor-directed agents as novel anti-HIV-1 therapies. Curr. Top. Med. Chem. 2004, 4, 1017-1034 and references therein.